True Leaf Medicine International Ltd.

  • WKN: A14NM1
  • ISIN: CA89785C1077
  • Land: Kanada

Nachricht vom 17.02.2017 | 10:08

True Hemp Pet Chews Are Coming to New Zealand

DGAP-News: True Leaf Medicine International Ltd. / Key word(s): Expansion/Alliance

17.02.2017 / 10:08
The issuer is solely responsible for the content of this announcement.


True Hemp Pet Chews Are Coming to New Zealand

With agreement to feature product in New Zealand's largest retail pet chain, True Leaf Pet enters Asia Pacific market for the first time

Vancouver, Canada, February 17, 2017 - True Leaf Pet has entered into an agreement with Liberty Premium Pet Products of Christchurch, New Zealand, to distribute True Hemp innovative pet chews to Animates pet retail stores across the country.

While True Hemp is sold across North America and in England and Germany, this is the first time the product will be sold in the Asia Pacific region. Effective April 2017, True Hemp will be sold exclusively in all Animates stores throughout NZ, also via the Animates e-commerce website, and in Animates Vetcare clinics.

Animates is New Zealand's largest pet retail chain.

"Liberty is proud to be representing True Hemp in New Zealand," said Liberty's Managing Partner Carl Rees. "With no other comparable hemp-based therapeutic dog products already on the market in New Zealand, we're enthusiastic about the release of True Hemp and eager to see the response of dog owners to True Hemp."

Hemp is coming into its own as health-conscious consumers worldwide recognize the benefits of the plant for themselves and their pets. True Hemp innovative chews come in three varieties: True Hemp(TM) CALMING to provide anxiety support, True Hemp(TM) HEALTH to provide antioxidant support and True Hemp(TM) - HIP+JOINT to provide joint support.

"The growth of the True Hemp brand has been the success story of 2016 for True Leaf Pet," said True Leaf CEO Darcy Bomford. "We've doubled sales from quarter to quarter, and now we're getting 2017 off to a great start working with Liberty in New Zealand. It's hard to believe we're now on three continents in only our second year."

Liberty was established in 2011 and has warehousing and offices based in Christchurch, New Zealand. Liberty imports premium brand pet products from North America companies. Liberty services the entire geographic area of New Zealand (both north and south islands) and has strong supplier partnerships with New Zealand's leading pet retail chains, including Animates.

About True Leaf

True Leaf Medicine International Ltd., through its wholly-owned subsidiary 'True Leaf Pet', has entered the $104.9 billion global pet care industry with a line of hemp-focused pet chews and supplements marketed through natural pet health and veterinary channels in Europe, Canada, and the United States. The company has also filed an application under Health Canada's Access to Cannabis for Medical Purposes Regulations (ACMPR) to become a Canadian licensed producer through its 'True Leaf Medicine' subsidiary. It has passed through the preliminary and enhanced screening process of Health Canada's review and is currently awaiting security clearance and 'pre-licensing inspection' approval. www.trueleaf.com

Media Contact:
Paul Sullivan
BreakThrough Communications
O: 604-685-4742
M: 604-603-7358

Investor Contact:
Kevin Bottomley
Director and Corporate Relations
M: 778-389-9933
E: kevin@trueleaf.com
www.trueleaf.com



17.02.2017 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



show this

Anleihe im Fokus

EYEMAXX Real Estate AG: EYEMAXX begibt Wandelanleihe im Volumen von bis zu 20,376 Mio. Euro

Kupon:4,5%

Bezugsfrist: bis 12. April 2017 (12.00 Uhr)

Öffentliches Angebot:bis 18. April 2017 (12.00 Uhr)

Laufzeit:bis einschließlich 15. Dezember 2019

ISIN: DE000A2DAJB7

GBC im Fokus

Neovacs S.A.: Kursziel auf 3,30 € angehoben

In den letzten Monaten hatte die Neovacs S.A. einen positiven Newsflow. Im Vordergrund steht die Vertriebspartnerschaft für den chinesischen Markt, wodurch sich bis nach dem ersten Vermarktungsjahr Gesamterträge von bis zu 65 Mio. € ergeben können. Zudem verläuft der klinische Zulassungsprozess des IFNα-Kinoid zur Behandlung von SLE (Systemischer Lupus) und Dermatomyositis planmäßig. Wir haben in unsere Bewertung aktualisiert und ein Kursziel von 3,30 € je Aktie (bisher: 2,90 €) ermittelt. Das Rating lautet weiter KAUFEN.

Event im Fokus

65. m:access Analystenkonferenz

Datum: 06.04.2017
Zeit: 09:30 - 17:00 Uhr
Ort: Börse München
Karolinenplatz 6
80333 München

News im Fokus

Vonovia SE: 93,09 % der conwert-Aktionäre nehmen das Übernahmeangebot von Vonovia an

27. März 2017, 18:18

Aktueller Webcast

Manz AG

Annual Report 2016

30. März 2017

Aktuelle Research-Studie

Ergomed plc

Original-Research: Ergomed plc (von GBC AG): Kaufen

29. März 2017